Risk of tumor transmission in transplantation from donors with primary brain tumors: an Australian and New Zealand registry report

Chui, A.K.K; Herbertt, Karen L; Wang, L.S; Kyd, G.; Hodgeman, G.K.; Verran, Deborah; DeLeon, Cristina; Sheil, A. G. R.

doi:10.1016/s0041-1345(98)01989-7

Cited by 62 publications

(38 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several retrospective reports have been published, but the risk of tumor transmission from donor-related CNS malignancies still remains uncertain. [1][2][3][4] Some studies reported an absence of donor transmission of malignancy, 2,3 wheras Buell et al 1 showed that 23% of the recipients showed donor malignancy transmission. On the other hand, a more recent study concluded that donor tumor transmission is uncommon, but also emphasized that donors with a history of CNS tumors are an exception.…”

Section: Discussionmentioning

confidence: 99%

Intermediate-term Outcome in Lung Transplantation From a Donor With Glioblastoma Multiforme

Chen

Karolak

Cypel

et al. 2009

The Journal of Heart and Lung Transplantation

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Intermediate-term Outcome in Lung Transplantation From a Donor With Glioblastoma Multiforme

Chen

Karolak

Cypel

et al. 2009

The Journal of Heart and Lung Transplantation

View full text Add to dashboard Cite

“…3,4,7,12 Despite the consensus that these organs should not be transplanted because of the risk of cancer transmission, 5,13,14 the incidence of donor-related tumors is in fact extremely low. [3][4][5][6][7] The donor-related tumor death rate is also low, particularly when compared with the waiting-list mortality, 15 which would be increased further by the exclusion of donors with a malignant CNS tumor. Guidelines for the use of organs from donors with malignant CNS tumors were prepared recently in Europe on the basis of the Cincinnati Transplant Tumor Registry.…”

Section: Discussionmentioning

confidence: 99%

“…2 Because there are so few reports on the transmission of malignancy to recipients after the transplantation of organs from such donors, the subject is controversial. [3][4][5][6][7] Kaposi's sarcoma (KS) is one of the most frequent malignant tumors arising de novo in immunodepressed patients. 8 Extrahepatic KS has been reported in 2.8% of hepatic transplant recipients, 9 and tends to be cutaneous in a solid organ transplant setting.…”

Section: Introductionmentioning

confidence: 99%

Kaposi's Sarcoma After Liver Transplantation from a Donor with a History of Ventriculoperitoneal Shunt and Craniotomy for Primary Central Nervous System Lymphoma: Report of a Case

et al. 2007

View full text Add to dashboard Cite

The transplantation of organs from donors who have undergone shunt surgery or craniotomy for a malignant central nervous system (CNS) tumor is controversial. We report a case of Kaposi's sarcoma (KS) developing as a result of immunosuppression in the recipient of a liver transplant from a donor who underwent craniotomy and ventriculoperitoneal shunt surgery for primary CNS lymphoma. Polymerase chain reaction assay did not isolate human herpes virus-8 in the Kaposi lesions. To our knowledge, this is the only case ever reported of KS developing after liver transplantation from a donor with lymphoma. Thus, with appropriate screening to exclude possible dissemination, patients with a history of high-grade primary CNS lymphoma treated by ventriculoperitoneal shunt and craniotomy may be accepted as donors.

show abstract

“…Of these donors, there were eight with a high-grade glioma and five with a medulloblastoma. They reported no cases of donor-derived malignancy at mean follow-up of 40 months [13]. Furthermore, according to the UNOS registry (USA) review from 2002 of 397 donors with a history of primary CNS tumors, from whom 1220 organs were transplanted and after the follow-up of 36-months, no tumor transmission to the recipient was observed.…”

Section: Primary Tumors Of the Central Nervous Systemmentioning

confidence: 99%

Patients with Primary Brain Tumors as Organ Donors

et al. 2015

View full text Add to dashboard Cite

Organ transplant is now the treatment of choice for many end-stage diseases. The success of solid organ transplantation is accompained by a severe shortage of available organs for those currently awaiting transplantation. In recent years, there has been an increasing demand for organs, but not a similar increase in the supply leading to a severe shortage of organs for transplant that resulted in increasing waiting times for recipients. This has resulted in expanded donor criteria to include older donors and donors with mild diseases. Malignancy is considered a contra-indication to organ donation, with a few possible exceptions. There is a significant controversy in the transplant literature around the use of organs from donors with primary brain tumors (PBT). While case reports and registry data have certainly documented transmission of PBT with resultant morbidity and even mortality, the loss of quality and quantity of life by those on the waiting list remains a staggering and sobering reality. Ultimately the decision regarding transplantation from such donors lies with the transplanting team that should weigh the risk of donor tumor transmission against the risk of their patient dying on the waiting list.

show abstract

Risk of tumor transmission in transplantation from donors with primary brain tumors: an Australian and New Zealand registry report

Cited by 62 publications

References 7 publications

Intermediate-term Outcome in Lung Transplantation From a Donor With Glioblastoma Multiforme

Intermediate-term Outcome in Lung Transplantation From a Donor With Glioblastoma Multiforme

Kaposi's Sarcoma After Liver Transplantation from a Donor with a History of Ventriculoperitoneal Shunt and Craniotomy for Primary Central Nervous System Lymphoma: Report of a Case

Patients with Primary Brain Tumors as Organ Donors

Contact Info

Product

Resources

About